| 1 |
34549837 | Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. | 2022 Jan |
1 |
| 2 |
35197069 | Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference. | 2022 Feb 23 |
2 |
| 3 |
35314092 | Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel. | 2022 Jul |
2 |
| 4 |
33904646 | Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. | 2021 Jul |
1 |
| 5 |
33981608 | Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. | 2021 |
1 |
| 6 |
34043207 | Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival. | 2021 Jul |
5 |
| 7 |
31672485 | PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium. | 2020 Jan |
1 |
| 8 |
32091336 | Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines. | 2020 |
1 |
| 9 |
32194730 | γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer. | 2020 Mar |
2 |
| 10 |
32206132 | Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging. | 2020 Feb |
1 |
| 11 |
32363164 | Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer. | 2020 |
1 |
| 12 |
32606932 | Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer. | 2020 |
2 |
| 13 |
32785928 | Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic. | 2020 Aug 12 |
1 |
| 14 |
33116879 | PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. | 2020 |
2 |
| 15 |
33486495 | Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. | 2020 |
1 |
| 16 |
30560837 | Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. | 2019 Mar-Apr |
4 |
| 17 |
30703190 | Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. | 2019 May 1 |
2 |
| 18 |
30987844 | Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial. | 2019 Sep |
1 |
| 19 |
31098427 | Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. | 2019 May |
1 |
| 20 |
31183025 | Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis. | 2019 May 6 |
1 |
| 21 |
31185946 | Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report. | 2019 Jun 11 |
1 |
| 22 |
32684578 | [CLINICAL OUTCOMES OF ABIRATERONE ACETATE FOR TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE ANALYSIS]. | 2019 |
2 |
| 23 |
28905815 | PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. | 2018 Mar-Apr |
2 |
| 24 |
29063869 | Role of chemotherapy in prostate cancer. | 2018 May-Jun |
1 |
| 25 |
29261442 | Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. | 2018 Feb 1 |
3 |
| 26 |
29274813 | Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. | 2018 Jun |
3 |
| 27 |
29722038 | Long-term abiraterone withdrawal syndrome. | 2018 Oct |
1 |
| 28 |
29802777 | Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. | 2018 Oct |
1 |
| 29 |
29946852 | [Neuroendocrine prostate cancer]. | 2018 Jul |
1 |
| 30 |
30048718 | Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. | 2018 Oct 14 |
1 |
| 31 |
30051622 | Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. | 2018 Oct |
1 |
| 32 |
30072309 | Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer. | 2018 Dec |
1 |
| 33 |
30283980 | No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer. | 2018 Dec |
2 |
| 34 |
31158090 | Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. | 2018 Dec |
1 |
| 35 |
27692811 | Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer. | 2017 Apr |
1 |
| 36 |
28171710 | Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. | 2017 Jun 15 |
1 |
| 37 |
28608931 | The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. | 2017 Sep 15 |
1 |
| 38 |
28855993 | Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era. | 2017 Oct |
3 |
| 39 |
29063171 | [Neuroendocrine prostate cancer]. | 2017 Nov |
1 |
| 40 |
29164346 | Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. | 2017 Nov 21 |
2 |
| 41 |
26991851 | Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare. | 2016 Dec |
3 |
| 42 |
27057826 | Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. | 2016 Apr |
6 |
| 43 |
27793943 | Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. | 2016 Nov |
1 |
| 44 |
27919966 | Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. | 2016 Dec |
1 |
| 45 |
27995113 | Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study. | 2016 Dec |
1 |
| 46 |
28740046 | INITIAL EXPERIENCE OF THE ENZALUTAMIDE TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER. | 2016 |
1 |
| 47 |
28799570 | A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. | 2016 Jan-Mar |
1 |
| 48 |
24947139 | Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. | 2015 May |
3 |
| 49 |
25683983 | Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer. | 2015 Mar |
2 |
| 50 |
25726498 | Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. | 2015 May |
1 |